These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16803540)

  • 81. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers.
    Broaddus RR; Lu KH
    Front Biosci; 2006 Sep; 11():2077-80. PubMed ID: 16720294
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Report of a germline double heterozygote in MSH2 and PALB2.
    Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Patsea E; Lypas G; Nasioulas G
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1242. PubMed ID: 32853479
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The importance of family history in young patients with endometrial cancer.
    Berends MJ; Kleibeuker JH; de Vries EG; Mourits MJ; Hollema H; Pras E; van der Zee AG
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):139-41. PubMed ID: 10206404
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.
    Martin SA; McCarthy A; Barber LJ; Burgess DJ; Parry S; Lord CJ; Ashworth A
    EMBO Mol Med; 2009 Sep; 1(6-7):323-37. PubMed ID: 20049736
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Hereditary aspects of endometrial adenocarcinoma.
    Sumoi R; Hakala-Ala-Pietilä T; Leminen A; Mecklin JP; Lehtovirta P
    Int J Cancer; 1995 Jul; 62(2):132-7. PubMed ID: 7622285
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Correlation between body mass index and prevalence of hereditary nonpolyposis colorectal cancer in Korean patients with endometrial cancer.
    Yoo HJ; Joo J; Seo SS; Kang S; Yoo CW; Park SY; Lim MC
    Int J Gynecol Cancer; 2012 Feb; 22(2):267-72. PubMed ID: 22274318
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice.
    Kovtun IV; Harris KJ; Jatoi A; Jevremovic D
    Carcinogenesis; 2011 Jul; 32(7):1085-92. PubMed ID: 21551128
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma.
    Lu X; Ying Y; Zhang W; Li R; Zhang J
    Cell Biol Int; 2023 Jan; 47(1):201-215. PubMed ID: 36208091
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Risk factors for endometrial cancer according to familial susceptibility.
    Fornasarig M; Campagnutta E; Talamini R; Franceschi S; Boz G; Scarabelli C; Andreaus CM; Scozzari G; Valentini M
    Int J Cancer; 1998 Jul; 77(1):29-32. PubMed ID: 9639390
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A Case of Perimenopausal Endometrial Cancer in a Woman with MSH2 Germline Mutation.
    Heo EJ; Park JM; Lee EH; Lee HW; Kim MK
    J Menopausal Med; 2013 Dec; 19(3):143-6. PubMed ID: 25371881
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A Pan-Cancer Analysis on the Systematic Correlation of MutS Homolog 2 (MSH2) to a Malignant Tumor.
    Yao H; Cao Z; Yong H; Zhang X; Zhang X; Li W; Zhi S; Wu W
    J Oncol; 2022; 2022():9175402. PubMed ID: 35368899
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Familial endometrial adenocarcinoma.
    Sandles LG
    Clin Obstet Gynecol; 1998 Mar; 41(1):167-71. PubMed ID: 9504234
    [No Abstract]   [Full Text] [Related]  

  • 93. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
    Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
    Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
    [TBL] [Abstract][Full Text] [Related]  

  • 94. G-C heterozygosis in mutS homolog2 as a risk factor to hereditary nonpolyposis colon cancer in the absence of a family medical history.
    Arvayo-Zatarain JA; Grijalva-Chon JM; Castro-Longoria R; Varela-Romero A
    Indian J Hum Genet; 2011 May; 17(2):90-3. PubMed ID: 22090720
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Expression of hPOT1 in HeLa cells and the probability of gene variation of hpot1 Exon14 in endometrial cancer are much higher than in other cancers.
    Liu F; Pu XY; Huang SG; Xiang GM; Jiang DN; Hou G; Huang DN
    Asian Pac J Cancer Prev; 2012; 13(11):5659-63. PubMed ID: 23317234
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Somatic polymerase epsilon mutations as another route leading to loss of DNA MMR protein expression in endometrial carcinoma-reply.
    Tafe LJ
    Hum Pathol; 2018 Jun; 76():170. PubMed ID: 29630911
    [No Abstract]   [Full Text] [Related]  

  • 97. Familial aggregation of carcinoma of the endometrium.
    Lynch HT; Lynch J; Conway T; Watson P; Coleman RL
    Am J Obstet Gynecol; 1994 Jul; 171(1):24-7. PubMed ID: 8030707
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution.
    Rush CM; Goodfellow PJ
    Gynecol Oncol; 2019 Jan; 152(1):1-2. PubMed ID: 30611321
    [No Abstract]   [Full Text] [Related]  

  • 99. Molecular classification in endometrial cancer - are we ready?
    Rychlik A; Bidzinski M
    Ginekol Pol; 2023; 94(1):1-2. PubMed ID: 36748253
    [No Abstract]   [Full Text] [Related]  

  • 100. Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report.
    Feng Y; Cao Y; Yuan M; Chen R; Ji X; Hu X
    Oncol Lett; 2019 Nov; 18(5):5085-5090. PubMed ID: 31612019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.